April 5, 2022 News by Marta Figueiredo, PhD #AAN2022 ā Long-term Evobrutinib Safe, Effective in Relapsing MS Long-term treatment with evobrutinib safely and effectively reduces the rate of relapses in adults with relapsing forms of multiple sclerosis (MS), according to 2.5 years of data from a Phase 2 extension study. These findings ā supporting evobrutinibās therapeutic potential in relapsing MS ā were shared in an…
December 16, 2021 News by Yedida Y Bogachkov PhD Management Programs May Help Keep Fatigue Stable Over Long-term Fatigue management ā whether through a symptom-specific self-management program or through general education regarding managing multiple sclerosis (MS) ā may help people with MS in keeping fatigue levels stable in the long term, a recent study suggests. Indeed, the benefits of such programs were found to remain in effect…
October 18, 2021 News by Marta Figueiredo, PhD #ECTRIMS2021 ā Early Ocrevus Slows MS Better Versus 2-year Delay Editorās note: TheĀ Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13ā15. GoĀ here to see the latest stories from the conference. Early use of…
July 7, 2020 News by Marta Figueiredo, PhD Study: Mavenclad Shows Long-term Effectiveness at Preventing MS Relapses, Disease Progression MavencladĀ (cladribine) prevents relapses and disease progression in more than half of patients with relapsing forms of multiple sclerosis (MS) for at least five years after the last dose, according to a real-life study from Italy. These findings, based on real-world data from Italian MS patients previously treated…
January 16, 2018 News by Patricia Inacio, PhD Long-term Rituxan Treatment Is Effective and Safe in MS, Study Shows The approved lymphoma therapy Rituxan (rituximab) has shown promise as a treatment for Ā multiple sclerosis. A new study indicates the Genentech treatment is effective and safe against neurological diseases like MS for up to seven years. The research, āLong-term safety of rituximab induced peripheral B-cell depletion in…
September 19, 2016 News by Patricia Silva, PhD #ECTRIMS2016 – Treatment of Progressive MS May Have Delayed Result There might be years-long lags in response to disease-modifying drugs in patients with progressive forms of multiple sclerosis (MS), according to a study that analyzed data from two large clinical trials of progressive MS patients. The study fuels the idea that clinical trials of disease-modifying drugs for progressive MS need…
August 11, 2016 News by Patricia Silva, PhD Early Disease Activity in MS Seen to Have Little Long-Term, Prognostic Value A large study of multiple sclerosis patients (MS) came to the conclusion that clinical and brain imaging assessments drawn from magnetic resonance imaging (MRI) scansĀ areĀ poor measures of long-term prognosis for patients. The study, āLong-term evolution of multiple sclerosis disability in the treatment era,ā published in the journal…